Deborah Rathjen
Chief Executive Officer chez BIOASIS TECHNOLOGIES INC.
Fortune : 714 $ au 31/03/2024
Profil
Deborah A.
Rathjen is currently the Executive Chairman, President & CEO at biOasis Technologies, Inc. She is also the Chief Executive Officer, MD & Director at Carina Biotech Pty Ltd., the Chairman at Neurofit SAS, the Director at Australian National Fabrication Facility Ltd., a Member at Higher Education South Africa, and a Member at Australian Institute of Co. Directors.
Previously, she served as the Chief Executive Officer & Executive Director at Bionomics Ltd.
from 2000 to 2019.
She was also the Chairman at AusBiotech Ltd.
from 2008 to 2014 and the General Manager-Business Development at Arana Therapeutics Ltd.
in 2000.
Dr. Rathjen holds a doctorate degree from Macquarie University and an undergraduate degree from Flinders University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/01/2023 | 178 571 ( 0,22% ) | 714 $ | 31/03/2024 |
Postes actifs de Deborah Rathjen
| Sociétés | Poste | Début |
|---|---|---|
| BIOASIS TECHNOLOGIES INC. | Chief Executive Officer | 11/03/2019 |
Australian Institute of Co. Directors
 Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Corporate Officer/Principal | - |
Higher Education South Africa
 Higher Education South Africa Miscellaneous Commercial ServicesCommercial Services Higher Education South Africa provides organizational services for higher education membership. The private company is based in Pretoria, South Africa. | Corporate Officer/Principal | - |
| Australian National Fabrication Facility Ltd. | Director/Board Member | - |
Neurofit SAS
 Neurofit SAS Medical/Nursing ServicesHealth Services Neurofit SAS operates as a preclinical contract research organization specializing in the evaluation of treatments for central and peripheral nervous system disorders. It develops new models and tests new molecules to facilitate preclinical drug such as acute oral toxicity study, translational model of DTH, and diabetic neuropathy. The company was founded in 1996 and is headquartered in Illkirch, France. | Chairman | - |
Carina Biotech Pty Ltd.
 Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Chief Executive Officer | - |
Anciens postes connus de Deborah Rathjen
| Sociétés | Poste | Fin |
|---|---|---|
| BIONOMICS LIMITED | Chief Executive Officer | 31/01/2019 |
AusBiotech Ltd.
 AusBiotech Ltd. Miscellaneous Commercial ServicesCommercial Services AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008. | Chairman | 01/01/2014 |
Arana Therapeutics Ltd.
 Arana Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arana Therapeutics Ltd. engages in researching and developing, investing, licensing, technology, producing, formulating and marketing peptides and related products for the human and animal pharmaceutical industries. It develops and provides human therapeutic products for the treatment of diseases in the areas of cancer and inflammation and products for fertility control in animals. The company was founded in 1985 and is headquartered in Macquarie Park, Australia. | Corporate Officer/Principal | 01/06/2000 |
| ░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Deborah Rathjen
| Macquarie University | Doctorate Degree |
| Flinders University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIONOMICS LIMITED | Health Technology |
| BIOASIS TECHNOLOGIES INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Cancer Therapeutics CRC Pty Ltd.
 Cancer Therapeutics CRC Pty Ltd. BiotechnologyHealth Technology Cancer Therapeutics CRC Pty Ltd. engages in research and development novel oncology drug and clinical diseases. It focuses in recombinant protein production, structural biology, DMPK, and translational cancer biology. The company was founded in 2007 and is headquartered in Melbourne, Australia. | Health Technology |
Arana Therapeutics Ltd.
Arana Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arana Therapeutics Ltd. engages in researching and developing, investing, licensing, technology, producing, formulating and marketing peptides and related products for the human and animal pharmaceutical industries. It develops and provides human therapeutic products for the treatment of diseases in the areas of cancer and inflammation and products for fertility control in animals. The company was founded in 1985 and is headquartered in Macquarie Park, Australia. | Health Technology |
Neurofit SAS
Neurofit SAS Medical/Nursing ServicesHealth Services Neurofit SAS operates as a preclinical contract research organization specializing in the evaluation of treatments for central and peripheral nervous system disorders. It develops new models and tests new molecules to facilitate preclinical drug such as acute oral toxicity study, translational model of DTH, and diabetic neuropathy. The company was founded in 1996 and is headquartered in Illkirch, France. | Health Services |
Higher Education South Africa
Higher Education South Africa Miscellaneous Commercial ServicesCommercial Services Higher Education South Africa provides organizational services for higher education membership. The private company is based in Pretoria, South Africa. | Commercial Services |
Australian Institute of Co. Directors
Australian Institute of Co. Directors Miscellaneous Commercial ServicesCommercial Services Australian Institute of Co. Directors is a non-profit organization that provides leadership on director issues. It offers governance education, director development, and advocacy. The organization was founded in January 1, 1990 and is headquartered in Sydney, Australia. | Commercial Services |
AusBiotech Ltd.
AusBiotech Ltd. Miscellaneous Commercial ServicesCommercial Services AusBiotech Ltd. operates as an Australian biotechnology membership company. The private company is based in Melbourne, Australia. and has subsidiaries in Australia. The company was founded by Liz Dallimore. Lorraine Chiroiu has been the CEO of the company since 2008. | Commercial Services |
| Australian National Fabrication Facility Ltd. | |
Carina Biotech Pty Ltd.
Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Health Technology |
